Method of treating diabetes type 2 by administering ultrarapid acting insulin

Patent metadata

Field	Value
Publication number	US-10857207-B2
Application number	US-201815910876-A
Country	US
Kind code	B2
Filing date	Mar 2, 2018
Priority date	Aug 11, 2008
Publication date	Dec 8, 2020
Grant date	Dec 8, 2020

Abstract

Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.

First claim

What is claimed is:

1. A method of treating diabetes comprising: selecting a patient with diabetes and in need of improved glycemic control, administering to said patient a first dose of an inhalable ultrarapid acting insulin preparation with at least one established meal at mealtime, and administering a second dose of the inhalable ultrarapid acting insulin 30 to 120 minutes after starting the at least one established meal if blood glucose levels are greater than 140 mg/dL; wherein the first dose and the second dose of the ultrarapid acting insulin comprise up to 120 IU of total insulin in a preparation comprising microparticles of 3,6-di(fumaryl-4-aminobutyl)-2,5-diketopiperazine and recombinant human insulin.

2. The method of claim 1 wherein the ultrarapid acting insulin preparation is a dry powder.

3. The method of claim 1 , wherein the ultrarapid acting insulin preparation is provided in an inhaler system comprising 4, 8, or 12 unit dose cartridges.

4. The method of claim 3 , wherein the ultrarapid acting insulin preparation is a crystalline dry powder.

5. The method of claim 1 , wherein the second dose of the ultrarapid acting insulin is 25% to 100% of the first dose.

Assignees

• Mannkind Corp

Inventors

• Richardson Peter
• Baughman Robert A
• Potocka Elizabeth
• Boss Anders Hasager
• Petrucci Richard

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61K9/0073

  Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M) · CPC title

• A61K38/28 Primary

  Insulins · CPC title

• A61K47/545

  Heterocyclic compounds (A61K47/558 takes precedence) · CPC title

• A61K38/16

  Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)} · CPC title